|
1
|
Ginsburg O, Bray F, Coleman MP, Vanderpuye
V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, et
al: The global burden of women's cancers: A grand challenge in
global health. Lancet. 389:847–860. 2017. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
3
|
Hayes EL and Lewis-Wambi JS: Mechanisms of
endocrine resistance in breast cancer: An overview of the proposed
roles of noncoding RNA. Breast Cancer Res. 17:402015. View Article : Google Scholar :
|
|
4
|
Shi Y, Zhao Y, Zhang Y, AiErken N, Shao N,
Ye R, Lin Y and Wang S: AFF3 upregulation mediates tamoxifen
resistance in breast cancers. J Exp Clin Cancer Res. 37:2542018.
View Article : Google Scholar :
|
|
5
|
Merikhian P, Ghadirian R, Farahmand L,
Mansouri S and Majidzadeh-A K: MUC1 induces tamoxifen resistance in
estrogen receptor-positive breast cancer. Expert Rev Anticancer
Ther. 17:607–613. 2017. View Article : Google Scholar
|
|
6
|
Jiang Q, Zheng S and Wang G: Development
of new estrogen receptor-targeting therapeutic agents for
tamoxifen-resistant breast cancer. Future Med Chem. 5:1023–1035.
2013. View Article : Google Scholar
|
|
7
|
Rao RD and Cobleigh MA: Adjuvant endocrine
therapy for breast cancer. Oncology (Williston Park). 26:541–547,
550, 552. 2012.
|
|
8
|
Jordan VC and O'Malley BW: Selective
estrogen-receptor modulators and antihormonal resistance in breast
cancer. J Clin Oncol. 25:5815–5824. 2007. View Article : Google Scholar
|
|
9
|
Egeland NG, Lunde S, Jonsdottir K, Lende
TH, Cronin-Fenton D, Gilje B, Janssen EA and Søiland H: The role of
MicroRNAs as predictors of response to tamoxifen treatment in
breast cancer patients. Int J Mol Sci. 16:24243–24275. 2015.
View Article : Google Scholar :
|
|
10
|
Nass N and Kalinski T: Tamoxifen
resistance: From cell culture experiments towards novel biomarkers.
Pathol Res Pract. 211:189–197. 2015. View Article : Google Scholar
|
|
11
|
Nass N, Bromme HJ, Hartig R, Korkmaz S,
Sel S, Hirche F, Ward A, Simm A, Wiemann S, Lykkesfeldt AE, et al:
Differential response to α-oxoaldehydes in tamoxifen resistant
MCF-7 breast cancer cells. PLoS One. 9:e1014732014. View Article : Google Scholar :
|
|
12
|
Viedma-Rodriguez R, Baiza-Gutman L,
Salamanca-Gomez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz
Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D:
Mechanisms associated with resistance to tamoxifen in estrogen
receptor-positive breast cancer (review). Oncol Rep. 32:3–15. 2014.
View Article : Google Scholar
|
|
13
|
Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu
Y, Ouyang Y and He Z: Cloning and functional characterization of
TCRP1, a novel gene mediating resistance to cisplatin in an oral
squamous cell carcinoma cell line. FEBS Lett. 585:881–887. 2011.
View Article : Google Scholar
|
|
14
|
Peng B, Gu Y, Xiong Y, Zheng G and He Z:
Microarray-assisted pathway analysis identifies MT1X & NFKB as
mediators of TCRP1-associated resistance to cisplatin in oral
squamous cell carcinoma. PLoS One. 7:e514132012. View Article : Google Scholar :
|
|
15
|
Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang
Y and He Z: TCRP1 promotes radioresistance of oral squamous cell
carcinoma cells via Akt signal pathway. Mol Cell Biochem.
357:107–113. 2011. View Article : Google Scholar
|
|
16
|
Liu X, Wang C, Gu Y, Zhang Z, Zheng G and
He Z: TCRP1 contributes to cisplatin resistance by preventing Pol β
degradation in lung cancer cells. Mol Cell Biochem. 398:175–183.
2015. View Article : Google Scholar
|
|
17
|
Wang C, Liu H, Qiu Q, Zhang Z, Gu Y and He
Z: TCRP1 promotes NIH/3T3 cell transformation by over-activating
PDK1 and akt1. Oncogenesis. 6:e3232017. View Article : Google Scholar :
|
|
18
|
Lin YS, Lin YY, Yang YH, Lin CL, Kuan FC,
Lu CN, Chang GH, Tsai MS, Hsu CM, Yeh RA, et al: Antrodia
cinnamomea extract inhibits the proliferation of
tamoxifen-resistant breast cancer cells through apoptosis and
skp2/microRNAs pathway. BMC Complement Altern Med. 18:1522018.
View Article : Google Scholar :
|
|
19
|
Du J, Yang M, Chen S, Li D, Chang Z and
Dong Z: PDK1 promotes tumor growth and metastasis in a spontaneous
breast cancer model. Oncogene. 35:3314–3323. 2016. View Article : Google Scholar
|
|
20
|
Castel P, Ellis H, Bago R, Toska E, Razavi
P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, et
al: PDK1-SGK1 Signaling sustains AKT-independent mTORC1 activation
and confers resistance to PI3Kα inhibition. Cancer Cell.
30:229–242. 2016. View Article : Google Scholar :
|
|
21
|
Liu X, Feng M, Zheng G, Gu Y, Wang C and
He Z: TCRP1 expression is associated with platinum sensitivity in
human lung and ovarian cancer cells. Oncol Lett. 13:1398–1405.
2017. View Article : Google Scholar
|
|
22
|
Jia X, Zhang Z, Luo K, Zheng G, Lu M, Song
Y, Liu H, Qiu H and He Z: TCRP1 transcriptionally regulated by
c-Myc confers cancer chemoresistance in tongue and lung cancer. Sci
Rep. 7:37442017. View Article : Google Scholar :
|
|
23
|
Zhou C, Zhong Q, Rhodes LV, Townley I,
Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow
ME and Wang G: Proteomic analysis of acquired tamoxifen resistance
in MCF-7 cells reveals expression signatures associated with
enhanced migration. Breast Cancer Res. 14:R452012. View Article : Google Scholar :
|
|
24
|
Fan P, Yue W, Wang JP, Aiyar S, Li Y, Kim
TH and Santen RJ: Mechanisms of resistance to structurally diverse
antiestrogens differ under premenopausal and postmenopausal
conditions: Evidence from in vitro breast cancer cell models.
Endocrinology. 150:2036–2045. 2009. View Article : Google Scholar :
|
|
25
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar
|
|
26
|
Leung EY, Kim JE, Askarian-Amiri M, Joseph
WR, McKeage MJ and Baguley BC: Hormone resistance in two MCF-7
breast cancer cell lines is associated with reduced mTOR signaling,
decreased glycolysis, and increased sensitivity to cytotoxic drugs.
Front Oncol. 4:2212014. View Article : Google Scholar :
|
|
27
|
Nawata H, Bronzert D and Lippman ME:
Isolation and characterization of a tamoxifen-resistant cell line
derived from MCF-7 human breast cancer cells. J Biol Chem.
256:5016–5021. 1981.
|
|
28
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar
|
|
29
|
Gee JM, Shaw VE, Hiscox SE, McClelland RA,
Rushmere NK and Nicholson RI: Deciphering antihormone-induced
compensatory mechanisms in breast cancer and their therapeutic
implications. Endocr Relat Cancer. 13 (Suppl 1):S77–S88. 2006.
View Article : Google Scholar
|
|
30
|
Raimondi C and Falasca M: Targeting PDK1
in cancer. Curr Med Chem. 18:2763–2769. 2011. View Article : Google Scholar
|
|
31
|
Peng B, Yi S, Gu Y, Zheng G and He Z:
Purification and biochemical characterization of a novel
protein-tongue cancer chemotherapy resistance-associated protein1
(TCRP1). Protein Expr Purif. 82:360–367. 2012. View Article : Google Scholar
|
|
32
|
Parsons R: Human cancer, PTEN and the PI-3
kinase pathway. Semin Cell Dev Biol. 15:171–176. 2004. View Article : Google Scholar
|
|
33
|
Lin HJ, Hsieh FC, Song H and Lin J:
Elevated phosphorylation and activation of PDK-1/AKT pathway in
human breast cancer. Br J Cancer. 93:1372–1381. 2005. View Article : Google Scholar :
|
|
34
|
Di Blasio L, Gagliardi PA, Puliafito A and
Primo L: Serine/threonine kinase 3-phosphoinositide-dependent
protein kinase-1 (PDK1) as a key regulator of cell migration and
cancer dissemination. Cancers (Basel). 9:E252017. View Article : Google Scholar
|
|
35
|
Bayascas JR: PDK1: The major transducer of
PI 3-kinase actions. Curr Top Microbiol Immunol. 346:9–29.
2010.
|
|
36
|
Fyffe C and Falasca M:
3-Phosphoinositide-dependent protein kinase-1 as an emerging target
in the management of breast cancer. Cancer Manag Res. 5:271–280.
2013.
|
|
37
|
Emmanouilidi A and Falasca M: Targeting
PDK1 for chemosensitization of cancer cells. Cancers (Basel).
9:E1402017. View Article : Google Scholar
|
